130 related articles for article (PubMed ID: 30980254)
1. Selective antagonism of CRF1 receptor by a substituted pyrimidine.
Sakellaris S; Matsoukas MT; Karageorgos V; Poulaki S; Kuppast B; Margioris A; Venihaki M; Fahmy H; Liapakis G
Hormones (Athens); 2019 Jun; 18(2):215-221. PubMed ID: 30980254
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a stable tripeptide targeting the N-domain of CRF1 receptor.
Liapakis G; Karageorgos V; Andreadelis I; Holz GG; Dermitzaki E; Kordopati GG; Stylos EΚ; Spyridaki K; Poulaki S; Ntountaniotis D; Sakellaris S; Vanioti M; Kostagianni A; Marousis KD; Leonis G; Kokotos G; Venihaki M; Spyroulias GA; Tselios T; Margioris A; Tzakos AG; Mavromoustakos T
Amino Acids; 2020 Sep; 52(9):1337-1351. PubMed ID: 32996057
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of new thiazolo[4,5-d]pyrimidines as Corticotropin releasing factor modulators.
Kuppast B; Spyridaki K; Lynch C; Hu Y; Liapakis G; Davies GE; Fahmy H
Med Chem; 2014; 11(1):50-9. PubMed ID: 25059547
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of substituted pyrimidines as corticotropin releasing factor (CRF) receptor ligands.
Kuppast B; Spyridaki K; Liapakis G; Fahmy H
Eur J Med Chem; 2014 May; 78():1-9. PubMed ID: 24675175
[TBL] [Abstract][Full Text] [Related]
5. Structural-functional analysis of the third transmembrane domain of the corticotropin-releasing factor type 1 receptor: role in activation and allosteric antagonism.
Spyridaki K; Matsoukas MT; Cordomi A; Gkountelias K; Papadokostaki M; Mavromoustakos T; Logothetis DE; Margioris AN; Pardo L; Liapakis G
J Biol Chem; 2014 Jul; 289(27):18966-77. PubMed ID: 24838244
[TBL] [Abstract][Full Text] [Related]
6. Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications.
McCarthy JR; Heinrichs SC; Grigoriadis DE
Curr Pharm Des; 1999 May; 5(5):289-315. PubMed ID: 10213797
[TBL] [Abstract][Full Text] [Related]
7. 125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors.
Grigoriadis DE; Liu XJ; Vaughn J; Palmer SF; True CD; Vale WW; Ling N; De Souza EB
Mol Pharmacol; 1996 Sep; 50(3):679-86. PubMed ID: 8794910
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of 3-(2-pyridyl)pyrazolo[1,5-a]pyrimidines as potent CRF1 receptor antagonists.
Huang CQ; Wilcoxen KM; Grigoriadis DE; McCarthy JR; Chen C
Bioorg Med Chem Lett; 2004 Aug; 14(15):3943-7. PubMed ID: 15225703
[TBL] [Abstract][Full Text] [Related]
9. Evidence that corticotropin-releasing factor receptor type 1 couples to Gs- and Gi-proteins through different conformations of its J-domain.
Berger H; Heinrich N; Wietfeld D; Bienert M; Beyermann M
Br J Pharmacol; 2006 Dec; 149(7):942-7. PubMed ID: 17057757
[TBL] [Abstract][Full Text] [Related]
10. Discovery of corticotropin releasing factor 2 receptor selective sauvagine analogues for treatment of skeletal muscle atrophy.
Isfort RJ; Wang F; Tscheiner M; Donnelly E; Bauer MB; Lefever F; Hinkle RT; Mazur AW
J Med Chem; 2005 Jan; 48(1):262-5. PubMed ID: 15634020
[TBL] [Abstract][Full Text] [Related]
11. Determinants of corticotropin releasing factor. Receptor selectivity of corticotropin releasing factor related peptides.
Mazur AW; Wang F; Tscheiner M; Donnelly E; Isfort RJ
J Med Chem; 2004 Jun; 47(13):3450-4. PubMed ID: 15189041
[TBL] [Abstract][Full Text] [Related]
12. Corticotropin Releasing Factor Type 1 and 2 Receptor Signaling in the Medial Prefrontal Cortex Modulates Binge-Like Ethanol Consumption in C57BL/6J Mice.
Robinson SL; Perez-Heydrich CA; Thiele TE
Brain Sci; 2019 Jul; 9(7):. PubMed ID: 31330967
[TBL] [Abstract][Full Text] [Related]
13. Cyclopenta[d]pyrimidines and dihydropyrrolo[2,3-d]pyrimidines as potent and selective corticotropin-releasing factor 1 receptor antagonists.
Arban R; Benedetti R; Bonanomi G; Capelli AM; Castiglioni E; Contini S; Degiorgis F; Di Felice P; Donati D; Fazzolari E; Gentile G; Marchionni C; Marchioro C; Messina F; Micheli F; Oliosi B; Pavone F; Pasquarello A; Perini B; Rinaldi M; Sabbatini FM; Vitulli G; Zarantonello P; Di Fabio R; St-Denis Y
ChemMedChem; 2007 Apr; 2(4):528-40. PubMed ID: 17335099
[TBL] [Abstract][Full Text] [Related]
14. Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
Chen C; Wilcoxen KM; Huang CQ; Xie YF; McCarthy JR; Webb TR; Zhu YF; Saunders J; Liu XJ; Chen TK; Bozigian H; Grigoriadis DE
J Med Chem; 2004 Sep; 47(19):4787-98. PubMed ID: 15341493
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and SAR of 2-dialkylamino-4-arylpyrimidines as potent and selective corticotropin-releasing factor(1) (CRF(1)) receptor antagonists.
Huang CQ; Grigoriadis DE; Liu Z; McCarthy JR; Ramphal J; Webb T; Whitten JP; Xie MY; Chen C
Bioorg Med Chem Lett; 2004 May; 14(9):2083-6. PubMed ID: 15080983
[TBL] [Abstract][Full Text] [Related]
16. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.
Hoare SR; Sullivan SK; Schwarz DA; Ling N; Vale WW; Crowe PD; Grigoriadis DE
Biochemistry; 2004 Apr; 43(13):3996-4011. PubMed ID: 15049707
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, structural optimization, SAR, in silico prediction of physicochemical properties and pharmacological evaluation of novel & potent thiazolo[4,5-d]pyrimidine corticotropin releasing factor (CRF) receptor antagonists.
Islam MR; Teleb M; Karageorgos V; Sakellaris S; Papadopoulos M; Pirmettis I; Fronczek FR; Liapakis G; Fahmy H
Eur J Pharm Sci; 2022 Feb; 169():106084. PubMed ID: 34856350
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a Pachymedusa dacnicolor-Sauvagine analog as a new high-affinity radioligand for corticotropin-releasing factor receptor studies.
Perrin MH; Tan LA; Vaughan JM; Lewis KA; Donaldson CJ; Miller C; Erchegyi J; Rivier JE; Sawchenko PE
J Pharmacol Exp Ther; 2015 May; 353(2):307-17. PubMed ID: 25736419
[TBL] [Abstract][Full Text] [Related]
19. Pyrazolo[1,5-a]pyrimidine CRF-1 receptor antagonists.
Wustrow DJ; Capiris T; Rubin R; Knobelsdorf JA; Akunne H; Davis MD; MacKenzie R; Pugsley TA; Zoski KT; Heffner TG; Wise LD
Bioorg Med Chem Lett; 1998 Aug; 8(16):2067-70. PubMed ID: 9873487
[TBL] [Abstract][Full Text] [Related]
20. 3-Aryl pyrazolo[4,3-d]pyrimidine derivatives: Nonpeptide CRF-1 antagonists.
Yuan J; Gulianello M; De Lombaert S; Brodbeck R; Kieltyka A; Hodgetts KJ
Bioorg Med Chem Lett; 2002 Aug; 12(16):2133-6. PubMed ID: 12127521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
